The two largest diversified healthcare companies struck deals yesterday that will propel them into vaccines, a key area for investors because of the pandemic flu threat.
Abbott Laboratories agreed to buy the drugs unit of Belgium’s Solvay in a $6.6 billion (€4.5 billion) cash deal.
Johnson Johnson bought an 18 per cent stake in Dutch biotech firm Crucell for $444 million as part of a flu vaccine deal, Crucell said. – (Reuters)
:quality(70)/cloudfront-eu-central-1.images.arcpublishing.com/irishtimes/VR3765MFOBH2NMV2QNICYDF67M.png)